Welcome to ASCO 2014 (#ASCO14), and this year’s annual meeting of the American Society of Clinical Oncology (ASCO) and the world’s largest cancer conference.
Healthcare innovation can take many forms. It can be a breakthrough in our understanding of the biology of cancer, or a disease that allows new drugs to target it in an effective way, for example. We also see it with advances in medical technology such as implants that can help restore vision or imaging techniques that may allow faster and more accurate diagnoses.
Dementia care is a “quiet crisis” that already touches many families and will touch many more as we live longer in our old age and the huge baby boomer population reaches retirement age.
I have previously written about my visits to cities that have biotech clusters or aspire to have them, so thought it would be of interest to look at Liverpool, in the north west region of the UK.
Liverpool – In the United Kingdom, 1 in 48 women will be diagnosed with ovarian cancer, with 90% of cases in those aged 45 or greater.
San Francisco – In the ASCO GU prostate cancer session yesterday morning one of the most interesting presentations was by Andrew J Armstrong, Associate Professor of Medicine and Surgery at the Duke Cancer Institute.
San Francisco – Tokai Pharmaceuticals is a case study in how not to do drug development.
This week sees the start of the American Society of Clinical Oncology Symposium on Genitourinary Cancers (ASCO GU) in San Francisco.
Cancer immunotherapy was described in the December 20, 2013 issue of Science magazine as their Breakthrough of the Year, but really, we are just scratching the surface of what can be achieved.
Clovis Oncology ($CLVS) is one of the winners at the JPM Morgan Healthcare conference (#JPM14) in San Francisco with a dramatic increase in share price over the past several days.